reason report
bottom line yesterday host first-ev analyst meet
nyc affirm view larg defect cartilag
repair market massiv under-penetrated highlight
maci game-chang advanc larg defect cartilag repair
sustain strong double-digit growth compani
forese futur specif heard two sport medicin
surgeon maci experi reinforc benefit
maci vs prior-gener carticel treatment option
maci ease-of-us surgeon shorter rehab time
believ drive maci adopt faster saw
carticel overal left meet confid vcel abil
deliv consist upsid street estim
least next year driven even higher number
orthoped surgeon util maci total
orthoped surgeon identifi sport medicin specialist
assum surgeon train higher
util new exist surgeon assum drop
procedur per surgeon per quarter vs procedur
per surgeon per quarter estim vs much-high
rate among physician one done implant sinc last
summer higher biopsi convers rate physician
train util maci continu ramp believ
vericel deliv least sale growth next year
mid-teen growth sustain go-forward basi high
end compar small-cap med-tech compani coverag
medic suppli devic
dcf compar compani
analysi ev/sal
net debt total capit
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
rate share outperform price target believ maintain
virtual monopoli highli under-penetrated articular cartilag repair market could
ultim see open-end growth long-term recently-launch maci product repair
larg cartilag defect seen sale growth acceler
mid-single-digit third-gener product
launch broadli one-of-it kind amount support clinic data includ
summit trial demonstr superior vs standard care microfractur year
carticel use first-gener product maci procedur base
eas use faster rehabilit time increas appeal physician
orthoped surgeon special sport medicin patient physician train
util maci continu ramp believ deliv least sale growth
next year mid-teen growth sustain go-forward basi high end
compar small-cap med-tech compani coverag univers
see signific opportun upsid alreadi above-street estim driven
even higher number orthoped surgeon util maci total
orthoped surgeon identifi sport medicin specialist model
current assum surgeon train exit exit
higher util new exist surgeon maci eas use benefit well
shorter rehabilit time could drive surgeon use even frequent
saw carticel current estim estim assum
maci procedur per surgeon project util drop maci
procedur per surgeon per quarter
unchang improv convers rate biopsi biopsi lead indic
maci sale growth acceler meaning last
quarter -- manag
disclos convers rate note held steadi maci
roll-out biopsi convert actual implant usual within month would
impli revenu growth first month could fall somewher
rang vs rang includ artifici inflat due
favor gross margin profil variabl cog total
well-posit significantli expand gross margin ultim achiev sustain oper
incom net profit earlier beyond also market
autolog epiderm product address sever burn market penetr
believ epicel alon sustain high-single-digit low-double-digit grower
takeaway investor day
earlier today host first ever-analyst meet nyc affirm view
larg defect cartilag repair market massiv under-penetrated
highlight maci game-chang advanc larg defect cartilag repair
sustain strong double-digit growth compani forese futur specif
heard two sport medicin surgeon maci experi reinforc
benefit maci vs prior-gener carticel treatment option maci ease-
of-us surgeon shorter rehab time believ drive maci adopt faster
saw carticel overal left meet confid vcel abil
deliv consist upsid street estim least next year
driven even higher number orthoped surgeon util maci
total orthoped surgeon identifi sport medicin specialist
assum surgeon train higher util new exist
surgeon assum drop procedur per surgeon per quarter vs
procedur per surgeon per quarter estim vs much-high rate among
physician one done implant sinc last summer higher biopsi
long revenu runway larg under-penetrated cartilag repair market ramp
adopt driven ease-of-us shorter rehab
manag highlight massiv under-penetrated cartilag repair market
long revenu runway maci sustain double-digit growth forese
futur manag reiter market estim cartilag defect patient
 estim dr strickland high volum sport medicin surgeon
done maci case sinc product launch also believ vcel
estim conserv given estim microfractur per year vs
estim base differ statist approach frame market peopl arriv
differ address market opportun estim regardless cartilag repair massiv
sleep market peg -- larg under-penetrated manag
estim penetr today patient popul vs estim
penetr base market estim believ maci deliv sustain
sale growth forese futur driven ramp adopt cartilag repair
surgeon perspect maci much easier use prior-gener
carticel believ mean faster adopt maci saw
carticel one physician note maci procedur take minut smaller
incis elimin need sutur dr strickland train fellow everi year
maci extrem easi dr strickland note anyon use scissor
maci ease-of-us allow bring physician board
surgeon train orthoped surgeon special sport medicin would
candid treat larg cartilag defect model current assum surgeon get
train per year could prove conserv given train surgeon
alon train surgeon maci compani could deliv signific upsid
current estim
patient perspect rehab time shorter improv outcom patient
return full weight-bear earli week vs week tradit treatment
option shorter rehab time make maci attract treatment option
gener activ group given younger patient popul tend athlet
physician panel meet yesterday expect convers rate
improv time today physician see mani referr patient
convers rate alreadi rel higher still believ convers rate broader
market improv surgeon climb learn curv identifi patient would
good fit on-going patient support program increas long-term convers rate
manag assess burn market opportun vs estim
epicel indic patient total burn surfac area tbsa
current focus target estim patient tbsa per manag
estim equat address market opportun estim epicel
price per procedur manag guid long-term growth high-singl digit
rate think conserv achiev compani
develop protocol kol burn center improv surviv rate identifi
patient quickli take biopsi earlier treatment eventu establish
epicel standard care burn center
provid better case support hotlin could remov barrier usag
drive util educ program aba american burn associ
could fuel physician awar peer-to-p influenc
financi outlook larg unchang tweak margin estim conserv
continu believ vcel gross margin continu improv case
volum ramp lower margin estim reflect margin cog high
end guidanc rang expect gross margin improv
deliv increment assum margin
cog nearli vs prior estim gross margin improv
increment ultim still believ peak gross margin
could approach even exceed full scale favor gross margin profil also
posit achiev profit faster lower revenu run rate mani
compar med-tech compani despit conserv gross margin project
still expect achiev ebit net incom profit
sport medicin surgeon view maci best treatment option patient
larg cartilag defect dr strauss note microfractur
benefit last one two year dr strickland suggest microfractur
isnt even option patella treatment option also shortfal
maci reimburs top payer access cover live
compani target top payer dr strauss note much easier
get reimburs maci help vcel commerci team time
need answer best procedur patient get reimburs
approv contrast zbh de novo product reimburs payer even
deni claim procedur
next month believ share trade arriv valuat
use discount cash flow dcf compar compani ev/sal analysi dcf
arriv valuat compar compani analysi arriv
month valuat rang valuat appli ev/sal multipl
sale estim current share trade
estim sale estim repres discount
view compar higher-growth small-cap med-tech group current trade
sale estim sale estim believ fundament support
valuat ev/sal rang assum modest discount due vcel
concentr investor base gener lack awar regen medicin market
broadli specif
risk valuat includ inabl execut physician train drive ramp maci
adopt potenti product recalls/regulatori issu either maci epicel
competit entrant current unawar need rais addit capit
reach profit could dilut exist sharehold inabl optim
variabl cog control oper expens order drive posit leverag
dollar thousand except per share amount
sold
research develop expens
impair intang asset
increas decreas fair valu warrant
 sale
sg sale
oper expens sale
compani report leerink partner estim
